Isatis indigotica is a biennial herbaceous cruciferous medical herb with antipyretic, antiviral, anti-inflammatory, and antiendotoxin activity. This study explored the chemotherapeutic potential of I indigotica on human hepatoma cells and investigated the mechanism by which metabolites from I indigotica inhibit hepatoma cell growth. Antitumor activity was discovered in dried I indigotica leaf chloroform extracts (CEDLI). In nude mice xenotransplanted with human hepatoma cells, CEDLI supplementation inhibited tumor growth by ~40% compared with nonsupplemented animals without affecting body weight/food intake. CEDLI induced sub-G1 cell cycle arrest and apoptosis in hepatoma cells. Furthermore, CEDLI activates p53 and Bax, reduces Bcl-2 expression, and causes mitochondrial stress and the release of apoptosis-inducing factor into the cytosol followed by its translocation into the nucleus, resulting in hepatoma cell apoptosis. This study provides novel in vivo evidence of I indigotica's antitumor activity. The chemotherapeutic activity against human hepatoma tumorigenesis was because of a distinguished caspase-independent apoptotic pathway.
Introduction
Liver cancer is the fifth most common cancer, with an incidence of 564 000 cases per year and a mortality of 548 600 cases per year in the world. 1 In Asia, the development of hepatocellular carcinoma (HCC) is frequently associated with chronic hepatitis and cirrhosis caused by persistent infection with hepatitis B virus or hepatitis C virus. HCC, the third leading cause of cancer-related death, 1 has attracted attention for its increasing worldwide incidence. 2 Identifying potential preventive and therapeutic treatments against human hepatoma would be highly significant.
Certain bioactive substances from natural herbs have been shown to significantly reduce the risk for various cancers. 3 Assessing bioactive substances for inhibition of tumor cell proliferation and survival is a common screen for chemopreventive and chemotherapeutic components of natural herbs. Isatis indigotica Fortune, a biennial herbaceous Cruciferae widely distributed in Asia, has been used as a medicinal herb in treatment of seasonal febrile diseases, 4 influenza, 5 viral pneumonia, 5 mumps, 4,5 sore throat, 4 and epidemic hepatitis 5, 6 in China since 50 bc. [4] [5] [6] I indigotica was reported to have antipyretic, 4,7 antiviral, [8] [9] [10] [11] anti-inflammatory, 4, 7 and anti-endotoxin activity. 7, 12 The extracts from I indigotica root were found to inhibit the writhing responses and decrease the licking time of mice. 4 It also reduced the paw edema induced by carrageenan and potently attenuated pyrexia induced by lipopolysaccharide (LPS) in rats. 4 It was reported to have antiviral activity against human cytomeglovirus (HCMV AD169) infected human embryo lung fibroblasts. 9 The leaves of I indigotica have anti-HSV-lI effect in HepG2 cells and in mice. 8 Co-injection of the I indigotica root extracts with DNA vaccine had a synergistic effect on the immune response against viral pathogens. 6 The ethanol fraction of I indigotica exhibited antiviral activity by inhibiting RANTES secretion from influenza A virus (H1N1) infected human bronchial epithelial A549 cells. 11 Extracts from roots of I indigotica inhibited tumor necrosis factor-α and interleukin-6 production by macrophages in vitro, inhibited fever induced by LPS in rabbits, and protected BCG-primed mice from LPS-induced lethality. 7 Leaves of I indigotica have been reported to have stronger pharmacological effect than roots. 12 These data have demonstrated the potent anti-infectious and anti-inflammatory activity of I indigotica, but the chemotherapeutic potential of I indigotica is unclear.
In recent years, blocking inflammation has become a promising approach for preventing carcinogenesis of the gastrointestinal tract. Arachidonic acid metabolism was involved in evolution of preneoplastic foci into nodules and HCCs in rat liver. 13 Studies evaluating anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors have been promising preventative agents in carcinogen-induced and genetically manipulated animal models of various cancers, including HCC. 13, 14 Therefore, suppression of inflammation has become one of the current strategies for chemoprevention of HCC.
Aberrant expression of COX-2 has been associated with hepatocarcinogenesis, and COX-2 inhibitors have effectively suppressed proliferation of HCC cells, 15 suggesting a potential chemotherapeutic activity of these compounds in addition to prevention. Numerous NSAIDs were also found to inhibit rat hepatoma cell proliferation. 16 In vitro studies have revealed that NS-398, a selective COX-2 inhibitor, and sulindac, an analog of NSAIDs, effectively inhibited growth of human hepatoma cell lines. 17, 18 These studies demonstrated that anti-inflammatory drugs targeting different pathways have antiproliferative activity; hence we postulated that with its strong anti-inflammatory effects, I indigotica could contain agents that exhibit potential chemotherapeutic activity against tumorigenesis. The objectives of the present study was to explore the chemotherapeutic potential of I indigotica on human hepatoma cells in vitro and in vivo and to further investigate the potential mechanisms by which I indigotica inhibits hepatoma cell proliferation.
Materials and Methods

Chemicals and Materials
Dried leaves and roots of I indigotica were obtained commercially (Herbal Source Biotechnology Co Ltd, Taichung, Taiwan). Identification of these crude drugs was confirmed by macroscopic and microscopic analysis according to the Chinese pharmacopoeia performed by Dr S S Chen from the Department of Agronomy at National Chung Hsing University.
For water extracts, 50 g of dried leaves were finely pulverized and boiled in 500 mL of water for 1 hour and then filtered. The extract was then evaporated under reduced pressure at 40°C. Crude extracts from methanol, ethyl acetate, chloroform, and hexane were prepared as previously described. 19 Briefly, 50 g of dried leaves were finely pulverized, dissolved in 500 mL of HPLC-grade methanol, ethyl acetate, or chloroform, and subjected to ultrasonic wave shaking for 1 hour at room temperature. The mixtures were then filtered through Whatman No. 1 filter paper into a roundbottomed flask. The residue was extracted for additional twice in the same manner. The combined extract from each solvent was then evaporated under reduced pressure at 40°C. We obtained 0.12, 0.39, and 1.78 g crude extracts from the ethyl acetate, chloroform, and hexane fractions, respectively, from each 50 g of dried I indigotica leaves. The condensed extracted products were redissolved in dimethyl sulfoxide (DMSO) to prepare a 500 mg/mL stock solution and stored at −20°C for cell culture experiments. Final concentration of DMSO did not exceed 0.1% in culture medium in any experiment.
Cell Culture and Treatment
Transformed human liver cell line Chang liver (FIRDI Ltd, Hsinchu, Taiwan), and the human hepatoma cell lines, HepG2, SKHep1 (ATCC, Rockville, MD) were grown in α-MEM (Eagle's modified essential medium) supplemented with 10% fetal calf serum and antibiotics at 37°C in 5% CO 2 . Huh-7, HA22T, Hep3B cells (kindly provided by Dr Chih-Yang Huang at China Medical University, Taichung, Taiwan) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA) and antibiotics at 37°C in 5% CO 2 . Experiments on all treatment conditions were performed in triplicate in each of the assays.
Cell Viability/Proliferation and Cell Death
The potential cytotoxic effects of water, methanol, ethyl acetate, chloroform, and hexane extracts from dried leaves of I indigotica were examined in all cell lines by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay at various concentrations. Chang liver cells, human hepatoma HepG2, SKHep1, Huh-7, and Hep3B cells were seeded (5 × 10 5 cells/well) in triplicate in 24-well culture plates for determination of viability. After overnight incubation, cells were treated with 0, 100, 500, 1000 μg/mL of different extracts from dried leaf I indigotica for 48 hours. Thereafter, MTT solution was added and incubated for 2 hours. The resulting formazan crystals were dissolved in acidic isopropanol, transferred into the 96-well plates, and read at 570 nm using a Sunrise ELISA reader (Tecan, Salzburg, Austria). The viability was assessed as percent cell viability compared with vehicle-treated control cells, which were assigned 100% viability. Chloroform extract of dried leaf of I indigotica (abbreviated as CEDLI) exhibited the most cytotoxic activity among the extracts and was therefore chosen for subsequent research on inhibition of cancer cell growth, and it cell death. In experiments using caspase inhibitors, HepG2 cells were exposed to concentrations at the approximate IC 50 of CEDLI (50 and 60 μg CEDLI/mL) for 48 hours in the absence or presence of caspase inhibitors (Z-VAD-FMK or Ac-DEVD-AMC at 20 μM). Cell viability was determined by MTT assay.
Morphology Observation
Approximately 4 × 10 6 cells were seeded in 6-well culture plates and then treated with CEDLI (60 or 100 μg/mL) for 48 hours. Cells were washed with phosphate-buffered saline (PBS), fixed (95% methanol, 5% acetic acid), and stained with DAPI (Sigma, St. Louis, MO). Photographs were recorded using an inverted microscope.
Cell Cycle Analysis
HepG2 cells were treated with 60 μg/mL CEDLI in triplicate for 36, 42, and 48 hours. After incubation, 5 × 10 6 cells were harvested, washed, and resuspended in cold PBS with cold ethanol. After incubation overnight at −20°C, cells were washed and stained with propidium iodide (PI; Sigma, St. Louis, MO)/Triton X-100 buffer in the dark and were immediately analyzed using the FACSCalibur system (Beckman Coulter Inc, Fullerton, CA). Percentages of cells in different cell cycle phases were calculated and presented.
Annexin V-FITC/PI Analysis
Induction of apoptosis by CEDLI was quantitatively determined by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit (Becton-Dickinson, Franklin Lakes, NJ) following the manufacturer's instructions. HepG2 cells were treated with CEDLI (60 μg/mL) for 12, 24, or 36 hours. After incubation, cells were harvested, washed with cold PBS, and resuspended in Annexin binding buffer supplemented with Annexin V-FITC and PI (50 μg/mL). The cells were incubated at 4°C in the dark for 10 minutes and immediately analyzed using the FACSCalibur system. To examine if a caspase inhibitor blocked the CEDLIinduced apoptosis, HepG2 cells were exposed to CEDLI (60 μg/mL) for 12, 24, or 36 hours in the absence or presence of caspase inhibitor Z-VAD-FMK or Ac-DEVD-AMC, then analyzed using the aforementioned methods. The experiments were performed in triplicate.
Western Blotting
After the treatments, cells were washed with PBS and lysed. The cytosolic fraction was obtained with the cytosol fractionation kit (BioVision, Mountain View, CA). The protein content was quantified using the BCA Protein Assay Kit (Pierce, Rockford, IL). Equal amounts of protein were denatured, separated on a 12% SDS-PAGE gel, and transferred onto a PVDF membrane. After blocking with 10% skim milk, the membranes were incubated with the indicated primary antibody: anti-Bcl-2 (1:500), anti-Bax (1:250), anti-P53 (1:200), anti-apoptosis-inducing factor (AIF, 1:1000) antibody (Abcam, Cambridge, MA), anti-caspase-3, or anti-caspase-9 (Cell Signaling, Danvers, MA) in Trisbuffered saline (TBS) containing 5% skim milk at 4°C overnight. Membranes were washed 3 times with TBS containing 0.1% Tween 20 (TBST) and the membranes were covered with horseradish peroxidase-linked anti-mouse or rabbit IgG (1:5000) at room temperature for 2 hours. The immunoblots were visualized with the enhanced chemiluminescence kit (New England Biolabs, Beverly, MA). To ensure equal protein loading, each membrane was stripped and reprobed with anti-β-actin (for cytosol fraction) or Lamin B1 (for nuclear fraction) antibody. All experiments were performed in triplicate.
Immunofluorescence Staining of AIF Translocation in Hepatoma Cells
Cells were seeded (5 × 10 4 cells/well) on 15-mm autoclaved cover glasses in 24-well culture plates. After overnight incubation, cells were either processed directly as control or treated with 60 μg/mL CEDLI for 36 hours. Samples were washed twice with PBS, incubated with 3.7% formaldehyde at room temperature, and permeabilized with 0.2% TritonX-100 for 10 minutes. The samples were blocked by immersing the cells in Image-iT FX Signal Enhancer (Invitrogen, Carlsbad, CA). After blocking, the samples were incubated with anti-AIF antibodies at 4°C overnight and immersed in PBS for 5 minutes thrice. Samples were incubated with the Alexa Fluor dye-labeled antibodies (5 μg/mL; Invitrogen) for 2 hours at 4°C and washed 3 times with PBS. The cover glasses were immersed in 20% glycerol/PBS. Fluorescence was visualized using a fluorescence microscope. In a separate experiment, Huh-7 cells (3 × 10 4 cells/well) were exposed to 60 μg/mL CEDLI for 24 hours, were stained with FITC-AIF, and counterstained with DAPI before analysis.
Effects of Dried Leaf Isatis indigotica on Tumor Growth In Vivo
Animal care and treatments were in accordance with institutional guidelines and approved protocol. Four-week-old female BALB/c nu/nu athymic mice (n = 10), weighing 14 o 16 g, were obtained from the National Laboratory Animal Center (Taipei, Taiwan). Mice were kept under specific pathogen-free conditions in a 12-hour light-dark cycle at 21.5°C and 60% relative humidity. Mice received an autoclaved standard diet Altromin (Altromin, Lage/ Lippe, Germany) and water ad libitum. A total of 3 × 10 6 human hepatoma Huh-7 cells, suspended in DMEM medium with Matrigel (BD, Franklin Lakes, NJ), were inoculated subcutaneously into the right flank of each mouse. Tumors developed in all mice except one mouse, which was excluded from the groups. When the tumor diameter reached 4 to 5 mm (~45 days post xenograft), animals were stratified by baseline tumor volume and evenly divided into the control and treatment groups to ensure similar baseline of tumor volumes. The same CEDLI extract preparation was used for both cell culture and animal experiments. The daily doses of dried leaf I indigotica in humans ranged from 37.5 to 300 g, 21 We obtained 2.4 g CEDLI from 300 g of dried leaf I indigotica, and we used a daily dose of 2.4 CEDLI that was extracted from 300 g dried leaves. A daily dose of 1.5 to 2.5 g concentrated extracts of dried leaf I indigotica has also been reported by others. 20 The daily dose used in the mice was calculated based on a 60 kg adult human. The human dose (2.4 g/60 kg or 0.04 g/kg body weight [BW]) was converted to mice (0.52 g/day/kg BW) according to the Food and Drug Administration conversion factor between human and mouse. 22 For a 25-g mouse consuming 5 g of diet per day, a diet with 0.26% CEDLI (w/w) contained approximately 0.013 g of CEDLI that was equivalent to 0.52 g CEDLI/kg mouse BW. The chloroform extract from the dried leaves was pulverized (CEDLI powder), carefully mixed with chow diet at 0.26% (w/w), autoclaved, and air-dried. Control animals received autoclaved diet without CEDLI extract. Mice were followed for the 60 days post-CEDLI initiation to investigate the effects of long-term CEDLI supplementation on tumor growth in vivo.
Body weight and tumor size were recorded every other day for 60 days until sacrifice. Tumor diameters were measured by a caliper every other day by the same personnel, and tumor volume was calculated as (width 2 × length)/2. 22 After 60-day CEDLI supplementation, animals were sacrificed and examined for gross pathology, including any evidence of abnormality in organ size and appearance. Organs were harvested and weighed, and one portion was snap-frozen and stored at −80°C. Tissues were fixed overnight in 10% (v/v) phosphate-buffered formalin and processed. The fixed tissues were dehydrated in ascending grades of ethanol, cleared in toluene, and embedded in paraffin wax. Sections were cut with microtome and mounted on superfrost slides (Fisher Scientific, Pittsburgh, PA) coated with 0.01% poly-l-lysine (Sigma-Aldrich). Sections of paraffin-embedded tissues were stained with hematoxylin-eosin (H&E) for routine histopathologic evaluation.
Immunohistochemical Analysis
To assess the effect of CEDLI supplementation on the proliferation in the human hepatoma cells in vivo, tumor tissue samples were immunohistochemically analyzed for proliferating cell nuclear antigen (PCNA). Paraffin-embedded sections on slides were deparaffinized by immersing the slides in fresh xylene for 10 minutes at 70°C. Samples were rehydrated by sequentially immersing the slides through graded ethanol washes (100%, 100%, 95%, and 75%) for 5 minutes each at room temperature. The slides were boiled in 10 mM citrate buffer (1.8 mM citric acid, 8.2 mM sodium citrate) for 20 minutes. The endogenous peroxidases were blocked by immersing the slides in 0.03% hydrogen peroxide. After the slides were immersed in PBS for 5 minutes thrice and blocked in 0.5% skim milk for 30 minutes, sections were incubated with the primary antibody of PCNA (1:500; BD, Franklin Lakes, NJ). After immersion in PBS, slides were incubated with the secondary antibody (DACO, Tokyo, Japan). Color was developed with the chromagen, 3,3-diaminobenzidine tetrahydrochloride (DACO, Tokyo, Japan), and the slides were counterstained with Mayer's hematoxylin. Apoptotic cells were identified by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) staining using Dead End Colorometric TUNEL System (Promega, Madison, WI). PCNA-and TUNEL-positive cells were quantified in each sample by counting brown-stained cells within the total number of cells from 5 randomly selected fields visualized at 400× magnification.
For the detection of AIF in tumor tissues, samples were incubated with the primary antibody for AIF (Epitomics, Burlingame, CA) for 1 hour, immersed in PBS 3 times, and incubated with the secondary antibody for 45 minutes. Color was developed with the chromagen 3,3-diaminobenzidine tetrahydrochloride and the slides counterstained with Mayer's hematoxylin. AIF expression in control and CEDLI samples was determined by counting the positive area with Image-pro Plus software within the total number of cells from 5 randomly selected fields at 400× magnification.
Statistics
The statistical significance of difference in the means among groups was determined by analysis of variance (ANOVA). Student's t test was performed to detect any significant difference in the means between control and treatment group (SYSTAT, SPSS, Chicago, IL). A P value <.05 was considered significant.
Results
Dried Leaf Isatis indigotica Extracts Decreased Hepatoma Cell Viability In Vitro
Extracts of dried leaves of I indigotica from hexane, ethyl acetate, and chloroform significantly reduced cell viability ( Figure 1 ). Chloroform extracts exhibited the most cytotoxic activity. At the concentration 100 μg/mL, treatment by the chloroform extract for 48 hours reduced cell viability to 43.3%, 13.8%, 14%, 40.4%, 26.6%, and 33.2% in Chang liver, HepG2, Huh-7, SKHep1, HA22T, and Hep3B cells, respectively, compared with untreated (vehicle only) cells. Most cells were still viable 48 hours after treatment with water or methanol extracts at the same concentration ( Figures 1A-1F ). Extracts from hexane, ethyl acetate, and chloroform exhibited a lower IC 50 than the water and methanol extracts. The chloroform fraction of dried leaf I indigotica (CEDLI) was the most potent in inhibiting cell proliferation, with an IC 50 <60 μg/mL in HepG2 (58 μg/mL) and Huh-7 (58 μg/mL) cells. The IC 50 of the water extract was >1000 μg/mL in all cell lines. Since the CEDLI fraction exhibited the most cytotoxic activity among the extracts, it was further investigated for tumor growth inhibition in vitro and in vivo.
HepG2 was used for investigating the molecular mechanism of cell death by CEDLI, because it was the most sensitive cell line examined. The IC 50 values of CEDLI were lower on most examined hepatoma cell lines compared with Chang liver cells, which suggested that chloroform extracts of dried leaf I indigotica could be more cytotoxic to malignant hepatoma cells than Chang liver cells.
Chloroform Extracts of Dried Leaf Isatis indigotica Induce Sub-G1 Phase Cell Cycle Arrest and Apoptotic Death in HepG2 Cells
Induction of tumor cell apoptosis is an effective strategy for chemotherapy. We next determined whether CEDLImediated inhibition of cell viability in hepatoma cells was a result of cell cycle arrest and the induction of apoptosis. Chromatin condensation and cell shrinkage were apparent in HepG2 cells treated with CEDLI at 60 μg/mL (Figure 2A ) and the sub-G1 cell population increased by approximately 5-fold (from 8.5% to 48.6%) at 48 hours ( Figure 2B ). Furthermore, Annexin V-FITC staining revealed that CEDLI also induced significant and time-dependent apoptosis. Percentage apoptotic cell population increased by more than 10-fold (from 2.3% to 30%) 36 hours posttreatment ( Figure 2C ). We concluded that the cytotoxic activities of CEDLI were associated with the induction of apoptotic machinery in HepG2 cells.
CEDLI Decreases the Expression of the Antiapoptotic Protein, Bcl-2 Whereas It Increases the Expression of the Proapoptotic Protein, Bax in HepG2 Cells
Bcl-2 family proteins, including cell death promoter Bax and inhibitor Bcl-2, were examined. CEDLI (60 μg/mL) significantly reduced the levels of anti-apoptotic protein Bcl-2 in a time-dependent manner (from 8 to 36 hours). Concurrently, the proapoptotic protein Bax was increased ( Figure 3A) . Quantifications of Bcl-2 and Bax proteins indicated that CEDLI induced apoptosis via alteration of pro-and anti-apoptotic protein expression in HepG2 cells ( Figure 3A ).
Chloroform Extracts of Dried Leaf
Isatis indigotica Lead to p53 Induction in HepG2 Cells p53, a pro-apoptotic transcription factor, regulates the expression of genes principally involved in cell cycle control, DNA repair, and apoptosis. 23 Being activated by the c-Jun-N-terminal kinase (JNK) family kinases when cells encounter stress, p53 suppresses the anti-apoptotic gene Bcl-2 and enhances the proapoptotic gene bax. 24 JNKs can also antagonize the function of the apoptotic protection of bcl-2 through phosphorylation, 25 leading to cell apoptosis. In the present study, CEDLI stimulated p53 expression in HepG2 cells from 2 to 12 hours posttreatment. JNK phosphorylation was not induced by CEDLI in HepG2 cells ( Figure 3A) . These results suggested that CEDLI treatment induced apoptosis in HepG2 cells by activating p53 and Bax expression while reducing Bcl-2 expression, independent of JNK activation.
Caspase Activation Is Not Associated With CEDLI-Mediated Apoptosis
Despite the significantly reduced viability, induced cell cycle arrest, increased cell apoptosis and increased BAX/Bcl2, neither capase-3 nor caspase-9 was activated by CEDLI at any time point ( Figure 3A ). In agreement with the unchanged caspase, the pan-caspase inhibitor z-VAD-fmk and caspase-3 specific inhibitor Ac-DEVD-AMC neither reduced the cytotoxicity of CEDLI ( Figure 3B ) nor did they rescue cell cycle arrest or reduce the apoptotic cell populations when compared with CEDLItreated cells or the vehicle controls ( Figure 3C ). Inhibition of intracellular caspase signaling did not protect against programmed cell death, suggesting a caspase-independent pathway involved in CEDLI-mediated cell death.
Activation of Caspase-Independent Pathway by CEDLI in HepG2 Cells
The levels of AIF were determined in the total cell lysates, cytosolic fractions, and nuclear fractions isolated from the homogenates of HepG2 cells exposed to 60 μg/mL chloroform extracts for 4, 12, and 24 hours. A modest release of AIF was detected as early as 4 hours, and its release became apparent in the cytosolic fractions 24 hours post-CEDLI treatment ( Figure 4A ). AIF expression in the nuclear fraction was significantly increased after CEDLI treatment ( Figure 4B ), and nuclear AIF localization was observed 24 hours after cells treated with CEDLI ( Figure 4C ). These results suggested that CEDLI-induced apoptosis in HepG2 cells is mediated by the translocation of AIF, which is independent of the caspase-mediated pathways. Thirty-six hours after CEDLI treatment, the mean percentage of CEDLI treated cells with translocated AIF (49.6% ± 4.1%) was significantly higher compared with control (1.5% ± 0.6%; P < .0001). We hypothesized that the altered pro-and anti-apoptotic proteins of Bcl-2 family and released apoptogenic factors into the cytosol were essential for the induction of apoptosis. These effects cause mitochondrial stress and lead to the release of AIF into the cytosol, followed by its translocation into the nucleus. Our current working model is depicted in Figure 4D .
Isatis indigotica Inhibited the Growth of Preestablished Tumor in a Nude Mice Model
The antitumor effect of CEDLI supplementation was then investigated in vivo. The initial approach of developing consistent, solid tumor nodules by injecting HepG2 cells into nude mice was unsuccessful; hence, we alternatively injected human hepatoma Huh-7 cells to generate tumor xenografts for our animal experiments. The IC 50 of CEDLI on HepG2 and Huh-7 were the lowest (58 μg/mL) among all cell lines examined.
CEDLI supplementation did not alter body weight, food intake ( Figure 5A ), or the organ weight (P > .05; Figure 5B ) in mice with established Huh-7 tumors. The mean daily food intake was 5.09 ± 0.45 g in nonsupplemented mice and 5.28 ± 0.96 g in the CEDLI (0.26%) supplemented mice (P = .43). No histopathology was observed in the kidney or liver from CEDLI-supplemented mice with established xenograft tumors ( Figure 5C ). Hepatic function indicators, AST and ALT, did not differ between CEDLI supplemented and nonsupplemented mice ( Figure 5D ). These results suggested that CEDLI (0.26%) supplementation for 60 days did not induce toxicity in the liver or kidney.
Tumor size was monitored throughout the 60-day supplementation period. A trend of tumor inhibition was observed 34 days after the CEDLI (0.26%) treatment started. The mean tumor volume was 284.4 ± 87.0 mm 3 in the CEDLI group and 403.1 ± 62.7 mm 3 in the nonsupplemented controls (P = .07; Figure 6A ). On day 39, mean tumor volume was significantly reduced in the CEDLI group (324.6 ± 115.4 mm 3 ) compared with controls (512.8 ± 33.7 mm 3 , P = .02). The difference in tumor volume became more drastic as tumor progressed. On day 60, the mean tumor volume in the CEDLI group was reduced by ~43% (686.9 ± 173.1 mm 3 ) compared with that of the HepG2 cells were treated with CEDLI (60 μg/mL) for different times and Bcl-2, Bax, procaspase-3, procaspase-9, p53, and JNK proteins expressions were determined by Western blot. Bax/Bcl-2 ratio are shown in bars as mean ± SD (n = 3). The asterisk (*) represents data that are significantly different from controls (P < .05). (B) Caspase inhibitors did not restore cell viability in CEDLI treated HepG2 cells. Cells were exposed to CEDLI (50 and 60 μg/ml) for 48 hours in the absence or presence of 20 μM caspase inhibitors (Z-VAD-FMK or Ac-DEVD-AMC) and then cells viability were determined by MTT assay. (C) Caspase inhibitors did not rescue cells from apoptosis induced by CEDLI (60 μg/mL). HepG2 cells were treated with CEDLI in the absence or presence of 20 μM caspase inhibitors. Cells viability and the percent apoptotic cells are presented in bars as mean ± SD (n = 3).
control group (1201.2 ± 151.5 mm 3 , P = .004). Furthermore, the mean tumor weight on day 60 was significantly reduced (controls vs CEDLI = 0.95 ± 0.08 vs 0.66 ± 0.19; P = .03; Figure 6B ). These results suggested that CEDLI (0.26%) supplementation inhibited tumor growth in vivo, and I indigotica has antitumor activity against human hepatoma cells.
Isatis indigotica Reduced Cell Proliferation and Induced AIF-Associated Apoptosis in HCC Cells In Vivo
Qualitative microscopic examination of PCNA-stained tumor sections showed a significant decrease in PCNA-positive cells in the CEDLI-supplemented mice (19.2% ± 1.8%) compared with nonsupplemented controls (28.5% ± 1.8%, P < .05; Figure 6C ). Further analysis was done to assess the apoptotic response of CEDLI supplementation. Microscopic examination of tissue sections showed an increased number of TUNEL-positive cells in CEDLI supplementation groups (4.1% ± 1.0%) versus controls (0.9% ± 0.2%, P < .05; Figure 6D ), yielding a 3.6-fold increase in the percentage of apoptotic cells. The percentage of apoptotic cells was conversely correlated with the tumor volume (r = −0.78, P = .003), and tumor weight (r = −0.68, P = .015) on day 60. These results suggested that antitumor activity of CEDLI involves both reducing tumor proliferation and increasing apoptotic death in vivo. Qualitative microscopic examination of AIF-stained tumor sections showed an increase of AIF-positive cells in the tumors of CEDLI supplemented mice compared with nonsupplemented controls ( Figure 6E ). The translocation of AIF was also observed in vitro in CEDLI-treated Huh-7 cells ( Figure 6F ). Taken together, the results suggested that CEDLI treatment reduced cell proliferation and induced AIF-associated apoptosis in HCC cells in vivo.
Discussion
The present study indicated that CEDLI induced apoptosis in HepG2 cells via a caspase-independent pathway. We discovered that (a) antitumor activity is present in dried /well) were exposed to CEDLI (60 μg/mL) for 24 hours, then stained with FITC-AIF, and counterstained with DAPI before analysis. Controls and CEDLI-treated cells are shown in the upper and lower panels, respectively. mechanism of cell death involved a distinct caspaseindependent, AIF translocation cell signaling pathway, and (g) long-term CEDLI supplementation reduced tumor growth and weight, HCC cell proliferation without detectable organ toxicity or abnormal histopathology in vivo.
Root and leaves of I indigotica have been widely used in the Asian populations for ameliorating inflammation and viral infections. In the present study, we provided evidence that dried leaves of I indigotica yield certain bioactive constituent(s) by chloroform extraction. At the dose at 2.4 g CEDLI/person/day, CEDLI could effectively inhibit hepatoma growth and induce apoptosis in vitro and in vivo. All hepatoma cell lines, including nonmetastatic and metastatic cell lines, were found to be highly sensitive to CEDLI. Compared with hepatoma cell lines, Chang liver cells were less susceptible to CEDLI at equivalent doses, although Chang liver cells are not considered to be an ideal model for healthy human liver cells currently. Chang liver (ATCC-CCL 13) was first derived from nonmalignant liver tissue. However, Chang cells from ATCC were later found to have a HeLa profile by DNA fingerprinting, and it is not an ideal cell model for healthy human liver cells. Among these celllines, Chang, HepG2, Huh-7, and Hep3B are well differentiated; yet HA22T and and SK1 are poorly differentiated. [23] [24] [25] HepG2, Chang, and SkHep1 display wild-type sequences in p53 coding regions 23, 24 ; whereas p53 in Hep3B was found deleted in exons 8-11. 26 HBV surface antigen was detected in Hep3B cells. 27 In the in vivo experiments, we alternatively injected human hepatoma Huh-7 cells to generate tumor xenografts for our animal experiments because the initial approach of developing consistent, solid tumor nodules by injecting HepG2 cells into nude mice was unsuccessful. We are aware that HepG2 and Huh-7 differ with respect to p53. HepG2 is "wild-type p53" and Huh-7 "mutant p53," 28 and it would be important to look at the exact mechanism of apoptosis in Huh-7 in the future.
On the other hand, we have shown antiproliferating effects of CEDLI on HepG2 (in vitro) and Huh-7 (in vivo). We also demonstrated that the caspase activation was absent in HepG2 (in vitro) and Huh-7 (in vivo); and AIF expression and translocation occurred in both cell lines. Therefore, we concluded that CEDLI inhibited hepatocellular cancer cell proliferation and induced cell death via caspase-independent, AIF translocation apoptotic pathway in vitro and in vivo. In the nude mouse model with hepatoma xenograft, CEDLI supplementation effectively reduced the number of PCNA expressing cells and increased TUNEL positive cells in the established tumor tissues. Importantly, no signs of hepatic or renal toxicity were detected in mice supplemented with CEDLI, as both architecture of these tissues and liver function indexes appeared normal.
In the present study, CEDLI induced p53 and resulted in a time-dependent decrease in the levels of anti-apoptotic proteins Bcl-2 with simultaneously increase in pro-apoptotic protein Bax. The p53 was increased between 2 and 12 hours and at 24 hours and the p53 induction was less significant than that of the earlier time points. The reason for a less increase in Bax/Bcl-2 ratio and in p53 at 36 hours is unknown. The decreased numbers of viable cells and proteins at the later time points may affect these results and create variations in these target proteins. Although the increase in Bax/Bcl-2 ratio was less significant at 36 hours, there was still a significant increase compared with the controls. The data comparing p53 and Bax/Bcl-2 ratio appeared to be in agreement. These data suggested that the antitumor activity of CEDLI involves p53 induction followed by the modulation of pro-and anti-apoptotic proteins. Initially, we expected procaspase-9 or procaspase-3 to be activated, as caspase-dependent apoptosis was previously considered as the major physiological and programmed form of cell death downstream of Bcl-2/ BAX homeostasis. However, CEDLI did not induce either procaspase-9 or procaspase-3 expression. These findings were carefully confirmed, as pan-caspase inhibitor z-VAD-fmk and caspase-3 specific inhibitor Ac-DEVD-AMC did not prevent apoptosis induced by CEDLI.
At 36 hours the Bax/Bcl-2 ratio in CEDLI-treated cells was lower than that at 24 hours, yet this ratio was still significantly increased compared with the controls. The cause of reduced Bax/Bcl-2 ratio at 36 hours is unknown since the increased Bax/Bcl-2 ratio was also less significant at 36 hours. We observed AIF release from the mitochondria at 24 hours and the translocation became apparent at 36 hours as observed by immunofluorescence ( Figure 4C ). Therefore, we postulated that p53 induced Bax/Bcl-2 ratio occurred first and AIF release and translocation occurred later ( Figure 4D ).
Induction of autophagic or apoptotic cell death in cancer cells by natural products could provide therapeutic benefit. Previously, the pharmacological actions of natural or dietbased products resulting in programmed cell death have mainly targeted the caspase family of cysteine proteases. Recently, it became clear that caspase activation is not necessarily required for all known programmed cell deaths, and more attention is focused on key molecules involved in nonapoptotic or caspase-independent programmed cell death pathways. 29, 30 These studies encouraged us to investigate the caspase-independent cell death. The mitochondrial protein AIF is a new therapeutic target involved in most of the caspase-independent programmed cell death systems, including programmed necrosis. 31 We found that CEDLI induced the release of AIF in a time-dependent manner, followed by its translocation to the nucleus and cell death of hepatoma cells. Furthermore, we provided evidence that CEDLI has the potential to kill metastatic hepatoma Huh-7 cells in vivo.
Several secondary metabolites have been identified in I indigotica, including tryptanthrin, indigo, indirubin, isoindigo, isoindirubin, 32 and indicant. 33 Among them, tryptanthrin, indigo, and indirubin were shown to have biological activities that affect the basic cell functions and were selected as the markers for quality control in I indigotica. 19 Other chemical constituents identified in I indigotica included alkaloids, organic acids, and glycosides. [33] [34] [35] [36] [37] [38] [39] [40] [41] Tryptanthrin was reported to induce apoptosis in leukemia cells through a caspase-3/Fas antigen pathway. 42 Indirubin was found to inhibit the expression of numerous NF-κB-regulated genes, including those involved in anti-apoptosis, proliferation, and invasion. However, these previous studies suggested that the chemotherapeutic activity of these active compounds was because of blocking cell cycle progression and/or triggering caspase-dependent apoptotic cell death. [43] [44] [45] [46] In contrast, our present study discovered a distinct mechanism by which chemical constituents/secondary metabolites from I indigotica induced caspase-independent apoptosis. These findings may suggest that the other unidentified chemical constituent(s) in dried leaf I indigotica extracts also have chemotherapeutic potential against human hepatoma. Studies on the efficacy of these active ingredients in dried leaves of I indigotica are underway. Induction of apoptosis in precancerous cells plays an important role as a protective mechanism against neoplastic development. Modulating the AIF pathway could be a new pharmacological approach to modulate aberrant programmed cell death. The positive outcomes in our in vivo study could form a strong basis for the development of a novel agent for human hepatoma prevention and/or intervention alone or as an adjuvant to known therapeutic agents for the treatment of hepatoma.
In summary, our present study demonstrated the in vitro and in vivo anticancer efficacy of chloroform extracts of dried leaf I indigotica against human hepatoma cells as well as elucidating mechanism of action. No apparent in vivo cytotoxicity was detected. We understand that this is a preliminary study and a number of issues need to be addressed in the future. These observations warrant further in vivo efficacy studies of bioactive compounds in I indigotica in mouse hepatoma models.
